Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Q2 Fiscal 2026 Earnings Highlights
COR logo

Cencora EPS Surges 128% Following Strategic OneOncology Acquisition and Robust U.S. Growth

COR8-KFiling Date: 5/6/2026
Cencora, Inc.
Description

What this story covers

Cencora delivered strong Q2 2026 results, highlighted by a 128% GAAP EPS surge and $78.4 billion in revenue. Driven by the OneOncology acquisition and specialty drug demand, the company raised its full-year guidance despite higher debt and margin pressures.

Story snapshot

CompanyCencora, Inc.
TickerCOR
VariantStandard detailed
Duration12:15
Filing type8-K
PeriodQ2 2026
IndustryHealthcare & Pharmaceuticals
Accession0001140859-26-000018
Sources1

Full Story Script

Content not available for this story.

Primary Sources

sec_filing8-KView on SEC.gov →

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in